Abstract

Research Article

Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks

Pandora Eloa Oliveira Fonseca, Jeremias Aguiar Azevedo, Sara Maria Gomes Bié and Sávio Benvindo Ferreira*

Published: 02 May, 2024 | Volume 8 - Issue 1 | Pages: 041-046

Type 2 diabetes mellitus (T2DM) is the most common cause of chronic kidney disease (CKD). CKD is characterized by progressive liver tissue damage and is an important risk factor for mortality due to renal and cardiovascular outcomes. Thus, randomized clinical trials have investigated the use of sodium-glucose cotransporter 2 (SLGT2) inhibitors as a promising therapy for patients with CKD and T2DM. This study aimed to analyze the benefits of using SGLT2 inhibitors in patients with CKD and T2DM to reduce mortality risks. To this end, a qualitative, descriptive methodological approach was adopted using a literature review in the PubMed, Embase, and VHL databases. The inclusion criteria were clinical trial articles, randomized or non-randomized, cohort studies, case-control studies, and open access, published in Portuguese and English, between 2018 and 2023 with topics associated with SGLT2 inhibitors, CDK, and T2DM patients. In this context, it was observed that the risk of death from CKD in patients treated with Canaglifozin was 30% lower than in those treated with a placebo and that Dapaglifozin prolonged survival. In this context, when assessing the progression of kidney disease or death from cardiovascular causes in patients taking Empagliflozin, only 13.1% achieved the outcome compared to 16.9% on placebo, so the drug safely reduces the risk of mortality. Consequently, SGLT2 inhibitors have shown excellent results in the treatment of CDK and T2DM, with a reduction in the risk of mortality, positive effects on reducing renal and cardiovascular outcomes, as well as prolonging survival.

Read Full Article HTML DOI: 10.29328/journal.apps.1001055 Cite this Article Read Full Article PDF

Keywords:

SLGT2 inhibitors; Chronic kidney disease; T2DM

References

  1. Daiana DB, Campos R. Chronic renal failure and its implications for metabolic systems. Uniandrade Magazine. 2017; 18:149–156. rev.uniandrade.br/index.php/revistauniandrade/article/view/691, https://doi.org/10.5935/revuniandrade.v18i3.691.
  2. da Silva TK. Diabetes Mellitus and Arterial Hypertension in Patients with Chronic Renal Failure on Dialysis. Integrative Review. Research, Society and Development. 2021; 10: e53410616121. https://doi.org/10.33448/rsd-v10i6.16121.
  3. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine [Internet]. 2019 Jun 13;380(24):2295–306.
  4. Saisho Y. SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes? Diseases. 2020; 8: 14. https://doi.org/10.3390/diseases8020014.
  5. Almeida CIF de. Impact of adverse effects of oral antidiabetics on adherence to therapy and quality of life in type 2 Diabetes Mellitus [Internet]. common.rcaap.pt. 2019 [cited 2024 Apr 28]. Available from: http://hdl.handle.net/10400.26/32923
  6. Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Adv Ther. 2022 Jan;39(1):148-164. doi: 10.1007/s12325-021-01994-2. Epub 2021 Nov 30. PMID: 34846711; PMCID: PMC8799531.
  7. Lo KB, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA, Rangaswami J. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. Cardiorenal Med. 2020;10(1):1-10. doi: 10.1159/000503919. Epub 2019 Nov 19. PMID: 31743918.
  8. Sridhar VS, Dubrofsky L, Boulet J, Cherney DZ. Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection. J Bras Nefrol. 2020 Oct-Dec;42(4):467-477. doi: 10.1590/2175-8239-JBN-2020-0100. PMID: 32926067; PMCID: PMC7860654.
  9. Silva PT. Use of SGLT2 Inhibitors as a New Drug Therapy in the Treatment of Chronic Kidney Disease in Patients with Diabetes Mellitus / Use of SGLT2 Inhibitors as a New Drug Therapy in the Treatment of Chronic Kidney Disease in Diabetes Mellitus Patients. Brazilian Journal of Development. 2022; 8: 34366–34381.
  10. Bezerra TG, Gonçalves ALG, Franco AM, Rossi BA, Gazzoni GAS, Winter ML. Cardiovascular repercussions of the use of SGLT2 inhibitors in patients with type 2 Diabetes Mellitus. Revista Eletrônica Acervo Saúde. 2021 May 18; 13(5):e6890.
  11. Silva GA, Carreira RG, Garcia WF, Cavasini Filho AE. SGLT2 inhibitors and their influence on the cardiovascular system: a systematic review. Electronic Magazine Acervo Saúde. 2020 Mar 26; (44):e3325.
  12. The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2022. https://doi.org/10.1056/nejmoa2204233.
  13. Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefánsson BV, Langkilde AM, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. J Am Soc Nephrol. 2021 Sep;32(9):2352-2361. doi: 10.1681/ASN.2021020167. Epub 2021 Jul 16. PMID: 34272327; PMCID: PMC8729835.
  14. Waijer SW, Vart P, Cherney DZI, Chertow GM, Jongs N, Langkilde AM, Mann JFE, Mosenzon O, McMurray JJV, Rossing P, Correa-Rotter R, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia. 2022 Jul;65(7):1085-1097. doi: 10.1007/s00125-022-05694-6. Epub 2022 Apr 21. PMID: 35445820; PMCID: PMC9174107.
  15. Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. PMID: 33338413.
  16. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. PMID: 33200891.
  17. Bloomgarden Z. The kidney and cardiovascular outcome trials. J Diabetes. 2018 Feb;10(2):88-89. doi: 10.1111/1753-0407.12616. PMID: 29031006.
  18. Carlos A. Delay in the Progression of Chronic Kidney Disease Using Sglt2 Inhibitors: Integrative Review. Research, Society and Development. 2023; 12: 14. e22212340670-e22212340670. https://doi.org/10.33448/rsd-v12i3.40670.
  19. Castro RMF. Diabetes Mellitus and Its Complications - A Systematic and Informative Review/ Diabetes Mellitus and Its Complications - a Systematic and Informative Review. Brazilian Journal of Health Review. 2021; 4:3349–3391, www.brazilianjournals.com/index.php/BJHR/article/download/24958/19902, https://doi.org/10.34119/bjhrv4n1-263.
  20. Fernández-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J. 2023 Jun 16;16(8):1187-1198. doi: 10.1093/ckj/sfad082. PMID: 37529652; PMCID: PMC10387399.
  21. Giugliano D, Longo M, Signoriello S, Maiorino MI, Solerte B, Chiodini P, Esposito K. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol. 2022 Mar 16;21(1):42. doi: 10.1186/s12933-022-01474-z. PMID: 35296336; PMCID: PMC8925229.
  22. Giusti CT, Carlos PN. Effectiveness and adverse events of Sglt2 Inhibitors. Journal of the Faculty of Medicine of Teresópolis. 4: 2020.
  23. Hahr AJ, Molitch ME. Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022. Am J Kidney Dis. 2022 May;79(5):728-736. doi: 10.1053/j.ajkd.2021.05.023. Epub 2021 Sep 30. PMID: 34600745.
  24. Handelsman Y. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther. 2019 Oct;36(10):2567-2586. doi: 10.1007/s12325-019-01054-w. Epub 2019 Aug 23. PMID: 31444707; PMCID: PMC6822830.
  25. Heerspink HJL, Sjöström CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJV, Rossing P, Correa-Rotter R, Kurlyandskaya R, Stefansson BV, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021 Mar 31;42(13):1216-1227. doi: 10.1093/eurheartj/ehab094. PMID: 33792669; PMCID: PMC8244648.
  26. Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC; DAPA-CKD Investigators. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020 Feb 1;35(2):274-282. doi: 10.1093/ndt/gfz290. PMID: 32030417; PMCID: PMC7005525.
  27. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018 Jul;94(1):26-39. doi: 10.1016/j.kint.2017.12.027. Epub 2018 May 5. PMID: 29735306.
  28. Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4. PMID: 34619106.
  29. Kalluri SR, Bhutta TH, Hannoodee H, Al Khalili M, Theik NWY, Raji OE, Shenwai P, Shah R, Khan S. Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review. Cureus. 2021 Sep 2;13(9):e17668. doi: 10.7759/cureus.17668. PMID: 34650848; PMCID: PMC8489544.
  30. Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, Cobble ME, McCullough PA. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019 Aug 5;18(1):99. doi: 10.1186/s12933-019-0903-4. PMID: 31382965; PMCID: PMC6683461.
  31. Kurata Y, Nangaku M. Dapagliflozin for the treatment of chronic kidney disease. Expert Rev Endocrinol Metab. 2022 Jul;17(4):275-291. doi: 10.1080/17446651.2022.2099373. Epub 2022 Jul 13. PMID: 35822873.
  32. Lin DS, Lee JK, Hung CS, Chen WJ. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia. 2021 Dec;64(12):2676-2686. doi: 10.1007/s00125-021-05529-w. Epub 2021 Sep 18. PMID: 34536085.
  33. McKee A, Al-Khazaali A, Albert SG. Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM. J Endocr Soc. 2020 Mar 20;4(5):bvaa037. doi: 10.1210/jendso/bvaa037. Erratum in: J Endocr Soc. 2020 Nov 18;4(12):bvaa134. Erratum in: J Endocr Soc. 2021 Jan 21;5(3):bvaa201. PMID: 32342023; PMCID: PMC7182131.
  34. Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Adv Ther. 2022 Jan;39(1):148-164. doi: 10.1007/s12325-021-01994-2. Epub 2021 Nov 30. PMID: 34846711; PMCID: PMC8799531.
  35. Mendes KDS. Use of bibliographic reference manager in the selection of primary studies in integrative review. Text & Context – Nursing. 2019; 28: www.scielo.br/j/tce/a/HZD4WwnbqL8t7YZpdWSjypj/?lang=pt, https://doi.org/10.1590/1980-265X-TCE-2017-0204.
  36. Mima A. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease. Adv Ther. 2021 May;38(5):2201-2212. doi: 10.1007/s12325-021-01735-5. Epub 2021 Apr 16. PMID: 33860925.
  37. Nunes LC. Association of SGLT2 Cotransporter Inhibitors with the Treatment of Heart Failure: A Literature Review. Electronic Magazine Acervo Médico. 2022; 10: e10336. https://doi.org/10.25248/reamed.e10336.2022.
  38. Roy A. Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement. Diabetes Therapy. 2020; 11: 2791–2827.
  39. Sarafidis P, Pella E, Kanbay M, Papagianni A. SGLT-2 inhibitors and nephroprotection in patients with diabetic and non-diabetic chronic kidney disease. Current Medicinal Chemistry. 2022 Aug 25; 29.
  40. Sarafidis P, Ortiz A, Ferro CJ, Halimi JM, Kreutz R, Mallamaci F, Mancia G, Wanner C; ‘Hypertension and the Kidney’ working group of the European Society of Hypertension (ESH) and the ‘European Renal and Cardiovascular Medicine’ (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA). Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. J Hypertens. 2021 Jun 1;39(6):1090-1097. doi: 10.1097/HJH.0000000000002776. PMID: 33443971.
  41. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015 Jan;75(1):33-59. doi: 10.1007/s40265-014-0337-y. PMID: 25488697.
  42. Kramer CK, Zinman B. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes. Annu Rev Med. 2019 Jan 27;70:323-334. doi: 10.1146/annurev-med-042017-094221. Epub 2018 Sep 26. PMID: 30256723.
  43. Stephens JW, Brown KE, Min T. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk. Diabetes Obes Metab. 2020 Apr;22 Suppl 1:32-45. doi: 10.1111/dom.13942. PMID: 32267078.
  44. Tian L, Ai S, Zheng H, Yang H, Zhou M, Tang J, Liu W, Zhao W, Wang Y. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. Front Pharmacol. 2022 Nov 24;13:986186. doi: 10.3389/fphar.2022.986186. PMID: 36506550; PMCID: PMC9731650.
  45. Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019 May;21(5):1237-1250. doi: 10.1111/dom.13648. Epub 2019 Mar 4. PMID: 30697905.
  46. Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol. 2022 May 25;21(1):83. doi: 10.1186/s12933-022-01512-w. PMID: 35614469; PMCID: PMC9134641.
  47. Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, Ueyama H, Fujisaki T, Saigusa Y, Yamaji T, Azushima K, Urate S, Suzuki T, Abe E, Wakui H, Tamura K. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021 Jan 7;20(1):14. doi: 10.1186/s12933-020-01197-z. PMID: 33413348; PMCID: PMC7792332.
  48. Yang Q, Lang Y, Yang W, Yang F, Yang J, Wu Y, Xiao X, Qin C, Zou Y, Zhao Y, Kang D, Liu F. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2023 Apr;198:110592. doi: 10.1016/j.diabres.2023.110592. Epub 2023 Feb 25. PMID: 36842477.
  49. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868. PMID: 30786725.
  50. Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2021 Jul 1;6(7):801-810. doi: 10.1001/jamacardio.2021.0660. PMID: 33851953; PMCID: PMC8047725.
  51. Zhang Q, Zhou S, Liu L. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis. Diabetol Metab Syndr. 2023 Jun 7;15(1):118. doi: 10.1186/s13098-023-01092-z. PMID: 37280615; PMCID: PMC10246111.
  52. Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W, Fu X, Xiao Y, Fu Q, Wang S, Zhao J. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol. 2022 Nov 5;21(1):232. doi: 10.1186/s12933-022-01676-5. PMID: 36335326; PMCID: PMC9637313.
  53. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28. PMID: 27470878.
  54. Silva LK, Morais BP, Pinto CT, Maciel JJR, Rezende LG, Moser LL, et al. Developmental mechanisms of euglycemic ketoacidosis associated with the use of SGLT2 inhibitors in patients with Diabetes Mellitus. Brazilian Journal of Health Review [Internet]. 2021 Oct 6 [cited 2023 Mar 24];4(5):21025–38. Available from: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/37014
  55. Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017 Jul;33(5). doi: 10.1002/dmrr.2886. Epub 2017 Feb 23. PMID: 28099783.
  56. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017 Oct 24;136(17):1643-1658. doi: 10.1161/CIRCULATIONAHA.117.030012. PMID: 29061576; PMCID: PMC5846470.

Figures:

Similar Articles

Recently Viewed

  • Hypercalcaemic Crisis Associated with Hyperthyroidism: A Rare and Challenging Presentation
    Karthik Baburaj*, Priya Thottiyil Nair, Abeed Hussain and Vimal MV Karthik Baburaj*, Priya Thottiyil Nair, Abeed Hussain, Vimal MV. Hypercalcaemic Crisis Associated with Hyperthyroidism: A Rare and Challenging Presentation. Ann Clin Endocrinol Metabol. 2024: doi: 10.29328/journal.acem.1001029; 8: 001-003
  • Physicians’ Anxiety Post-COVID Pandemic: A Cross-Sectional Study
    Ismail Hanine*, Mouna Chtibi, Kenza Hajjami, Siham Belbachir, Mohamed Kadiri and Abderrazzak Ouanass Ismail Hanine*, Mouna Chtibi, Kenza Hajjami, Siham Belbachir, Mohamed Kadiri, Abderrazzak Ouanass. Physicians’ Anxiety Post-COVID Pandemic: A Cross-Sectional Study. Arch Psychiatr Ment Health. 2024: doi: 10.29328/journal.apmh.1001054; 8: 032-037
  • Current anesthesıa for Cesarean Sectıon
    Demet Dogan Erol* and Ismail Aytac Demet Dogan Erol*, Ismail Aytac. Current anesthesıa for Cesarean Sectıon. Clin J Obstet Gynecol. 2018: doi: 10.29328/journal.cjog.1001011; 1: 061-066
  • Therapy of Walker Carcinosarcoma with Pectin and Cyclophosphane
    NY Alimzhanov, ISh Chakeev, BN Lepshin, IO Kudaibergenova, BA Shaimurzayeva, LV Serikova and Sh Jorobekova* NY Alimzhanov, ISh Chakeev, BN Lepshin, IO Kudaibergenova, BA Shaimurzayeva, LV Serikova, Sh Jorobekova*. Therapy of Walker Carcinosarcoma with Pectin and Cyclophosphane. J Radiol Oncol. 2023: doi: 10.29328/journal.jro.1001056; 7: 066-070
  • Acute Inflammatory Reaction After Radiotherapy to Bilateral Orbital Metastasis from Melanoma
    Christopher J Issa, Batoul Nasser*, Batoul Mazraani, Kevin T Eid, Bailey Loving and Thomas J Quinn and Muayad F Almahariq Christopher J Issa, Batoul Nasser*, Batoul Mazraani, Kevin T Eid, Bailey Loving, Thomas J Quinn and Muayad F Almahariq. Acute Inflammatory Reaction After Radiotherapy to Bilateral Orbital Metastasis from Melanoma. J Radiol Oncol. 2023: doi: 10.29328/journal.jro.1001054; 7: 056-057

Read More

Most Viewed

Read More

Help ?